Bill
S 868
Expands MA health‑care market oversight to tighten price monitoring and drug access: broader definitions, early price notices, and stronger confidentiality for submissions.
Note on source materials / title mismatch
The metadata you provided lists S 868 with the short title “Requires certain health insurance policies to include coverage for the cost of certain infant and baby formulas.” The bill text you provided, however, is titled the “Mobilizing and Enhancing Georgia’s Options for Building Accountability, Resilience, and Independence Act” (MEGOBARI Act) and the detailed docket text appears to be an act amending Massachusetts General Laws, chapter 6D, concerning health‑care market oversight and pharmaceutical access. Because the supplied text is the MEGOBARI/health‑care oversight bill, this summary focuses on the substance of that text. If you intended the infant‑formula coverage bill, please provide the full text or confirm which version to summarize.
Summary — MEGOBARI Act (Senate No. 868 / Senate Docket No. 1910)
Purpose
- Strengthen health‑care market oversight and improve pharmaceutical access by amending definitions, disclosure/notification requirements, data confidentiality, and the Health Policy Commission’s structure and authorities contained in chapter 6D of the Massachusetts General Laws.
Key provisions (from provided text)
- New or revised statutory definitions:
- “Benchmark cycle”: a two‑calendar‑year period used to calculate the projected annualized growth rate in total health‑care expenditures (section 1).
- “Biosimilar” and expanded definition for “brand name drug,” with references to federal statutes and data sources (section 1).
- “Early notice”: requires advanced notification from manufacturers for new products or price increases (section 2).
- “Pipeline drug”: new molecular entity with an NDA/BLA action date (section 4).
- “Provider organization”: broadened to include many organizational forms, including for‑profit‑owned providers and networks (section 5).
- “Total medical expenses”: defined as allowed claims plus non‑claims payments for a provider organization’s patient population (section 6).
- “Wholesale acquisition cost”: added with federal statutory reference (section 7).
- Confidentiality and public disclosure limitations:
- Replaces section 2A to require the Health Policy Commission to keep nonpublic clinical, financial, strategic, and operational submissions confidential unless consent is given or a public‑interest exception is invoked; explicitly exempted from public records law (section 8).
- Commission composition / expertise:
- Requires at least two pharmacists (including an independent pharmacist) on the commission (section 9).
- Policy focus broadened:
- Adds a statutory affordability mandate alongside cost growth monitoring (section 10).
- Other sections are truncated in the provided text; additional amendments addressing monitoring, notification (section 15A referenced), and enforcement are indicated elsewhere but not included in full.
Who would be affected
- Health carriers and insurers, provider organizations (physician groups, ACOs, networks), pharmacies (including independent pharmacists), pharmaceutical manufacturers (notification and pricing provisions), the Health Policy Commission, and ultimately patients/consumers through impacts on coverage, pricing transparency, and systemwide cost and affordability measures.
Procedural status and timeline (from provided actions)
- Introduced (filed) Jan 17, 2025 (Massachusetts docket references). Legislative actions in your record show multiple committee referrals and calendar placements (e.g., placed on Senate calendar; COMMITTED TO RULES as of 2025‑06‑13). Some provided actions appear to reflect U.S. Senate activity (committees, sponsors such as Sen. Shaheen), suggesting conflation of materials. Verify the jurisdiction (Massachusetts vs. U.S. Senate) and consult the official legislative website for current status and final text.
Potential impact and considerations
- Expanding definitions and adding procurement/price‑notice requirements could improve state monitoring of pharmaceutical pricing and cost drivers.
- Confidentiality protections may encourage stakeholder cooperation while limiting public access to sensitive submissions.
- Broader definition of “provider organization” and “total medical expenses” enables more comprehensive oversight of integrated health‑care arrangements.
- Requirements for manufacturer early notices and added pharmacist expertise on the commission could improve regulatory responsiveness but may raise administrative burdens for manufacturers and payers.
Recommendation
- Because the provided materials appear to be a composite of different bills/jurisdictions and the text is truncated, consult the official legislative source (Massachusetts Legislature bill page or the U.S. Senate bill registry, as applicable) for the complete, authoritative text and the current procedural status before using this summary for policy or advocacy work.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
